Sustained suppression of neointimal proliferation by sirolimus-eluting stents

Sousa, J. Eduardo; Costa, Marco; Abizaid, Alexander

doi:10.1016/s1062-1458(02)00554-8

Cited by 86 publications

(93 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The first study with rapamycin-eluting stent in humans showed an angiographic restenosis rate equal to 0% at 4 and 12 months 29,30 . The randomized studies showed a statistically significant reduction of the intra-stent restenosis rates at 8 months of 35.4%-41.7% for the conventional stent versus 3.2-3.9% for the rapamycin-eluting stent 31,32. Similarly, the RESEARCH study, which evaluated the performance of the rapamycin-eluting stent in the real world, i.e., in patients that were not selected by inclusion or exclusion criteria, confirmed these promising results in Intervention Cardiology practice, with an intra-stent restenosis rate of 6.3% at 6 months 33 .…”

Section: Discussionmentioning

confidence: 99%

Importância da interação entre a integrina Mac-1 dos leucócitos e a glicoproteína Iba das plaquetas para o recrutamento de leucócitos pelas plaquetas e para a resposta inflamatória à lesão vascular

Zago¹,

Simon²,

Wang³

et al. 2008

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

SummaryObjective: To assess the importance of the interaction between leukocyte integrin Mac-1 ( M 2 ) and platelet glycoprotein (GP) Ib-for leukocyte recruitment after vascular injury and the effect of the neutralization of the Mac-1-GPIb interaction on cell proliferation and the neointimal hyperplasia triggered by the vascular injury.Methods: A peptide called M2 or anti-M2 antibody was developed to block the Mac-1-GPIb interaction. This peptide was injected and compared to a control-peptide in C57B1/6J mice submitted to vascular injury of the femoral artery with a guide wire. One, five or 28 days after the vascular injury, the femoral arteries were removed for morphometric and immunohistochemical analyses.

show abstract

Section: Discussionmentioning

confidence: 99%

Importância da interação entre a integrina Mac-1 dos leucócitos e a glicoproteína Iba das plaquetas para o recrutamento de leucócitos pelas plaquetas e para a resposta inflamatória à lesão vascular

Zago¹,

Simon²,

Wang³

et al. 2008

Arq. Bras. Cardiol.

View full text Add to dashboard Cite

show abstract

“…Subsequent studies of the same cohort at 1 and 2 years continued to document sustained suppression of neointimal hyperplasia as detected with both IVUS and quantitative angiography (628,879). In the Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent (RAVEL) trial, 238 patients were randomly allocated between BMS and SES (624).…”

Section: Class Imentioning

confidence: 99%

“…Class IIa IVUS is reasonable for the following: tal studies to evaluate the efficacy of systemic and locally delivered antirestenotic therapies (624)(625)(626)(627)(628) or in clinical research trials to assess the effect of therapies for dyslipidemia on vascular wall and plaque structure. Historically, translesional pressure gradients were used as end points for early interventional cardiology procedures.…”

Section: Intravascular Ultrasound Imagingmentioning

confidence: 99%

“…Peer-reviewed publications of human DES implantation, including consecutive case series and randomized trials, are available for 3 polymer-based, drug-eluting, balloon-expandable stent systems (Table 30) (236,441,624,628,697,698,(879)(880)(881)(882)(883)(884)(885)(886)(887)(888): the antiproliferative, antimigratory, anti-inflammatory macrolide antibiotic rapamycin (sirolimus) affixed to a stent (Bx Velocity); the 7-hexanoyltaxol (QP2)-eluting polymer stent system (QuaDS); and the microtubule inhibitor paclitaxel (TAXUS) affixed to a stent. Each of these systems had undergone rigorous testing in animal models that demonstrated an intact endothelial layer and significant reductions in neointimal hyperplasia and inflammation.…”

Section: Class Imentioning

confidence: 99%

See 1 more Smart Citation

ACC/AHA/SCAI Practice Guidelines, February 21, 2006

Wilkins¹

2006

Circulation

349

View full text Add to dashboard Cite

“…Feasibility and safety studies employing a sirolimuseluting stent were initially performed in a nonrandomized fashion in patients with single Benestent type A lesions in São Paulo [19] and Rotterdam [4,15,20]. Using the Bx Velocity stent as a carrier, two varieties of drugeluting stents were manufactured.…”

Section: Initial Human Studiesmentioning

confidence: 99%

Polymer-Sirolimus-Eluting Stents in de Novo Lesions

Schuler

2004

Herz

View full text Add to dashboard Cite

Sirolimus has been shown to inhibit vascular smooth muscle cell proliferation and migration. Stents coated with a mixture of polymer and active drug achieved near total inhibition of neointimal hyperplasia in patients with de novo coronary lesions. Larger, randomized trials confirmed these initial results to a large extent; late luminal loss was not only reduced by > 70% in patients with type A lesions, but also in complex situations such as diabetic patients, long lesions, and small vessels < 2.5 mm. Registries containing several thousand patients, however, indicate that under realistic conditions the flawless results of the initial studies could not be reproduced in all patient groups.

show abstract

Sustained suppression of neointimal proliferation by sirolimus-eluting stents

Cited by 86 publications

References 0 publications

Importância da interação entre a integrina Mac-1 dos leucócitos e a glicoproteína Iba das plaquetas para o recrutamento de leucócitos pelas plaquetas e para a resposta inflamatória à lesão vascular

Importância da interação entre a integrina Mac-1 dos leucócitos e a glicoproteína Iba das plaquetas para o recrutamento de leucócitos pelas plaquetas e para a resposta inflamatória à lesão vascular

ACC/AHA/SCAI Practice Guidelines, February 21, 2006

Polymer-Sirolimus-Eluting Stents in de Novo Lesions

Contact Info

Product

Resources

About